



BREAKTHROUGH PEPTIDE THERAPEUTICS

Appendix 4E

Preliminary final report

Year ended 30 June 2016

Results for announcement to the market:			Current period (\$A'000)		Previous corresponding period (\$A'000)
Revenues from ordinary activities (item 1.1)	Down 80.09%	To	180	From	904
Profit (loss) from ordinary activities after tax attributable to members (item 1.22)	Up 33.03%	To	(3,979)	From	(2,991)
Net profit (loss) for the period attributable to members (item 1.11)	Down 33.03%	To	(3,979)	From	(2,991)
Dividends There are no dividend or distribution reinvestment plans in operation and there have been no dividend or distribution payments during the financial year ended 30 June 2016.					
Comments During the financial year the Company concluded an entitlement issue, raising \$8,789,780, after costs of the issue, from the allotment of 1,002,069,367 shares at \$0.01 per share. In the current period there was no fee for service income, the company concentrating instead on its own cancer program.					
Net tangible assets per ordinary security			30 June 2016	30 June 2015	
Net tangible assets			\$5,830,243	\$962,034	
Number of shares on issue at reporting date			2,004,138,734	1,002,069,367	
Net tangible assets per ordinary security			0.291 cents	0.096 cents	
Control Gained or Lost over Entities Not applicable					
Associates and joint ventures Not applicable					
Foreign Entities Accounting Framework Not applicable					
Audit/Review Status This Appendix 4E is based on audited accounts attached to this notice.					
The attached consolidated financial report for the year ended 30 June 2016 forms part of this Appendix 4E. This report should be read in conjunction with the Phylogica Limited 2016 Annual Financial Report and the notes contained therein.					